Lenalidomide and Melphalan for Newly Diagnosed Multiple Myeloma
Author Information
Author(s): Darrell White, Paul Macdonald, Meyer R. Shepherd
Primary Institution: Queen Elizabeth II Health Sciences Centre and Dalhousie University
Hypothesis
Can the combination of lenalidomide and melphalan improve outcomes for patients with newly diagnosed multiple myeloma?
Conclusion
The MY.11 trial aims to establish the tolerability and efficacy of lenalidomide combined with melphalan for treating newly diagnosed multiple myeloma.
Supporting Evidence
- Lenalidomide is a derivative of thalidomide that has shown promise in treating multiple myeloma.
- The MY.11 trial is designed to assess the safety and efficacy of lenalidomide combined with melphalan.
- Previous studies have shown that thalidomide combined with melphalan and prednisone improves outcomes for myeloma patients.
Takeaway
This study is testing a new medicine called lenalidomide with another medicine called melphalan to see if it helps people with a type of blood cancer called multiple myeloma.
Methodology
The MY.11 trial is a randomized phase II study evaluating the combination of lenalidomide and melphalan in newly diagnosed multiple myeloma patients.
Limitations
The study's initial treatment protocol was suspended due to dose-limiting toxicities observed in early patients.
Want to read the original?
Access the complete publication on the publisher's website